{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:55:07Z","timestamp":1790715307536,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":219,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinsp.2025.100757","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T03:01:49Z","timestamp":1755745309000},"page":"100757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neutralizing activity against Omicron subvariants BA.1, BA.2, and BA.4\/5 following the third SARS-CoV-2 vaccination in cancer patients undergoing chemotherapy"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-8309","authenticated-orcid":false,"given":"Jina","family":"Yun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6836-4682","authenticated-orcid":false,"given":"Bora","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5214-7430","authenticated-orcid":false,"given":"Hyuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0845-9994","authenticated-orcid":false,"given":"Sung Hee","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1280-7798","authenticated-orcid":false,"given":"Seong Hyeok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7605-801X","authenticated-orcid":false,"given":"Ji Youn","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3589-5847","authenticated-orcid":false,"given":"Hyun Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3055-3621","authenticated-orcid":false,"given":"Seong Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinsp.2025.100757_bib0001","unstructured":"Korea Disease Control and Prevention Agency. (August 28, 2023). National coronavirus (COVID-19) vaccination rate in South Korea as of August 28, 2023, by age group [Graph]. In Statista. Retrieved November 24, 2023, from https:\/\/www.statista.com\/statistics\/1358025\/south-korea-national-covid-19-vaccination-rate-by-age\/."},{"issue":"12","key":"10.1016\/j.clinsp.2025.100757_bib0002","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/cid\/ciac345","article-title":"Antibody response of heterologous vs homologous messenger RNA vaccine boosters against the severe acute Respiratory syndrome coronavirus 2 omicron variant: interim results from the PRIBIVAC study, a randomized clinical trial","volume":"75","author":"Poh","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.clinsp.2025.100757_bib0003","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3390\/vaccines9121379","article-title":"Serum antibody response comparison and adverse reaction analysis in healthcare workers vaccinated with the BNT162b2 or ChAdOx1 COVID-19 vaccine","volume":"9","author":"Lim","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"13","key":"10.1016\/j.clinsp.2025.100757_bib0004","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3346\/jkms.2023.38.e103","article-title":"Effects of omicron infection and changes in serum antibody response to wild-type, delta, and Omicron after a booster dose with BNT163b2 vaccine in Korean healthcare workers","volume":"38","author":"Lim","year":"2023","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.clinsp.2025.100757_bib0005","unstructured":"Mathieu E, Ritchie H, Rod\u00e9s-Guirao L, Appel C, Gavrilov D, Giattino C, et al. COVID-19 Pandemic. Our World in Data. 2020. Available from: https:\/\/ourworldindata.org\/coronavirus."},{"key":"10.1016\/j.clinsp.2025.100757_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.873596","article-title":"The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: a systematic review and meta-analysis","volume":"10","author":"Rahmani","year":"2022","journal-title":"Front Public Health"},{"issue":"14","key":"10.1016\/j.clinsp.2025.100757_bib0007","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clinsp.2025.100757_bib0008","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S2213-2600(23)00306-5","article-title":"Effectiveness of BNT162b2 BA.4\/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study","volume":"11","author":"Tartof","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100757_bib0009","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ajco.13959","article-title":"Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy","volume":"20","author":"Lim","year":"2024","journal-title":"Asia Pac J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clinsp.2025.100757_bib0010","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.3346\/jkms.2023.38.e139","article-title":"Eight-month follow-up after the third dose of BNT162b2 vaccine in healthcare workers: the question of a fourth dose","volume":"38","author":"Lim","year":"2023","journal-title":"J Korean Med Sci"},{"issue":"3","key":"10.1016\/j.clinsp.2025.100757_bib0011","doi-asserted-by":"crossref","first-page":"746","DOI":"10.4143\/crt.2022.1541","article-title":"Immunogenicity and safety of vaccines against coronavirus disease in actively treated patients with solid tumors: a prospective cohort study","volume":"55","author":"Baek","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100757_bib0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-022-01233-3","article-title":"Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis","volume":"15","author":"Sakuraba","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clinsp.2025.100757_bib0013","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4068\/cmj.2023.59.1.24","article-title":"Immune response to COVID-19 vaccination in hematologic malignancies: a mini-review","volume":"59","author":"Keshavarz","year":"2023","journal-title":"Chonnam Med J"},{"issue":"11","key":"10.1016\/j.clinsp.2025.100757_bib0014","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S1473-3099(23)00271-2","article-title":"Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study","volume":"23","author":"Nakakubo","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"44","key":"10.1016\/j.clinsp.2025.100757_bib0015","first-page":"1504","article-title":"The suspected coronavirus disease 2019 reinfection cases and vaccine effectiveness, The Republic of Korea","volume":"16","author":"Shim","year":"2023","journal-title":"Public Health Weekly Report"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593225001760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593225001760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:55:19Z","timestamp":1790711719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593225001760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":15,"alternative-id":["S1807593225001760"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2025.100757","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutralizing activity against Omicron subvariants BA.1, BA.2, and BA.4\/5 following the third SARS-CoV-2 vaccination in cancer patients undergoing chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2025.100757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100757"}}